2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMORecruiting
The main objective of this trial will be to get a better insight in the influence of age and age-related changes by internal and external factors on vaccine-induced immune responses and gain knowledge on the trajectory of immune decline in older…